newsfilter
← Latest News
Business Wire·

Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy

Adults with Duchenne muscular dystrophy demonstrated functional improvements exceeding natural history, following 28-day treatment with SAT-3247 Grip strength increased 118.6% and predicted forced vital capacity